Cargando…
Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their use
Pirfenidone (Esbriet(®)) is available as capsules containing 267 mg of pirfenidone and, more recently, as bioequivalent tablets containing 267, 534 or 801 mg of pirfenidone. Both formulations are indicated to treat idiopathic pulmonary fibrosis (IPF), with pirfenidone being shown to generally reduce...
Autor principal: | Lyseng-Williamson, Katherine A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019423/ https://www.ncbi.nlm.nih.gov/pubmed/30008572 http://dx.doi.org/10.1007/s40267-017-0459-x |
Ejemplares similares
-
Anakinra in Still’s disease: a profile of its use
por: Lyseng-Williamson, Katherine A.
Publicado: (2018) -
Burosumab in X-linked hypophosphatemia: a profile of its use in the USA
por: Lyseng-Williamson, Katherine A.
Publicado: (2018) -
Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use
por: Lyseng-Williamson, Katherine A.
Publicado: (2018) -
Macrogol (polyethylene glycol) 4000 without electrolytes in the symptomatic treatment of chronic constipation: a profile of its use
por: Lyseng-Williamson, Katherine A.
Publicado: (2018) -
Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA
por: McKeage, Kate, et al.
Publicado: (2018)